Astal Laboratories Ltd — Important, 30-05-2026: Company Update

Astal Laboratories confirmed no deviation in the utilization of funds for the quarter ended March 31, 2026. The company completed the acquisition of Sriven Pharmachem India Private Limited by issuing equity shares via a share swap, with no cash funds raised in this specific instance. Separately, from funds totaling 3.06 Cr raised for long-term requirements including capital expenditure and working capital, Astal Laboratories has utilized 2.86 Cr. This update assures investors that fund deployment aligns with stated objectives.